https://pharminent.com/eli-lilly-to-buy-trio-of-vaccine-developers-in-3-8bn-outlay/ 2026-05-26T14:48:59Z Pharminent en Eli Lilly to buy trio of vaccine developers in $3.8bn outlay 2026-05-26T12:28:39Z Blog https://pharminent.com/lillys-verve-gambit-pays-off-as-base-editor-cuts-cholesterol-in-early-study/ 2026-05-26T14:49:04Z Pharminent en Lilly's Verve gambit pays off as base editor cuts cholesterol in early study 2026-05-26T11:00:42Z Blog https://pharminent.com/all-eyes-on-revolution-bispecific-antibodies-and-more-at-asco26/ 2026-05-26T14:49:09Z Pharminent en All eyes on Revolution, bispecific antibodies and more at ASCO26 2026-05-26T04:32:00Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-may-25-2026/ 2026-05-25T19:35:14Z Pharminent en Strategic News Watch • May 25, 2026 2026-05-25T19:35:10Z Blog